Analysis updated on Oct. 16, 2026 (UTC) · Total · absolute moveSwitch to Alpha · Nasdaq
On Oct. 16, 2026, SIBN is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 5172 stocks scored that day.
Si-Bone, Inc. is a small-cap company with a market capitalization of $882M. It ranks number 38 by market capitalization among the 60 Surgical & Medical Instruments & Apparatus issuers in our coverage with a current forecast.
For SIBN, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 41.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 40.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected absolute price move over the horizon, market included. This is the number a price target is built from. Ratings: strong buy ≥ +5.0%, buy ≥ +3.4%, sell < +1.8%, strong sell < +0.8% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-16 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, SIBN included.
Follow SIBN free90D Total forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Surgical & Medical Instruments & Apparatus peers listed below that report each metric.
| Metric | SIBN | Rank |
|---|---|---|
| Market Cap | $882M | 38/60 |
| P/B Ratio | 4.84x | 26/55 |
| EPS | $-0.39 | – |
| Book Value/Share | $4.07 | – |
| Revenue/Share | $4.77 | – |
| FCF/Share | $-0.10 | – |
| Metric | SIBN | Rank |
|---|---|---|
| ROE | -8.0% | 21/41 |
| ROA | -5.9% | 24/44 |
| ROIC | -7.9% | 35/53 |
| Gross Margin | 79.5% | 7/53 |
| Operating Margin | -8.3% | 36/54 |
| Net Margin | -6.8% | 23/43 |
| EBT Margin | -6.7% | 34/54 |
| Tax Rate | 0.0% | – |
| Metric | SIBN | Rank |
|---|---|---|
| Current Ratio | 9.15x | 7/59 |
| Quick Ratio | 7.55x | 10/55 |
| D/E Ratio | 0.36x | 37/56 |
| Financial Leverage | 1.36x | 36/54 |
| Interest Coverage | -1.0x | 29/48 |
| Working Capital | $196M | 35/59 |
| Metric | SIBN | Rank |
|---|---|---|
| Operating Cash Flow | $2M | 36/55 |
| Free Cash Flow | -$4M | 30/50 |
| Capital Spending | -$7M | 17/50 |
| FCF/Sales | -2.0% | 32/49 |
| CapEx/Sales | 3.2% | 29/49 |
| Metric | SIBN | Rank |
|---|---|---|
| Asset Turnover | 0.86x | 15/50 |
| Receivables Turnover | 6.8x | 22/51 |
| Inventory Turnover | 1.1x | 43/51 |
| Fixed Assets Turnover | 9.8x | 18/52 |
| Days Sales Outstanding | 53 days | 30/51 |
| Days Inventory | 320 days | 9/51 |
| Payables Period | 71 days | 17/46 |
| Cash Conversion Cycle | 302 days | 6/42 |
| Metric | SIBN | Rank |
|---|---|---|
| Total Revenue | $214M | 38/52 |
| Operating Income | -$18M | 32/55 |
| Net Income | -$15M | 23/44 |
| R&D Expense | $18M | 44/53 |
| SG&A Expense | $217M | 34/53 |
| Cost of Goods Sold | $44M | 42/53 |
| Metric | SIBN | Rank |
|---|---|---|
| Shares Outstanding | 45M | – |
| Total Current Assets | $220M | 88.4% of assets |
| Cash & Short-term Investments | $33M | 13.3% of assets |
| Accounts Receivable | $31M | 12.5% of assets |
| Inventory | $38M | 15.4% of assets |
| Total Liabilities | $66M | 26.7% of assets |
| Short-term Debt | $16M | 6.2% of assets |
Companies classified under the same SEC industry code as Si-Bone, Inc. (Surgical & Medical Instruments & Apparatus): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Total) | Market Cap |
|---|---|---|
| SIBN Si-Bone, Inc. | ▶ | $882M |
| SYK Stryker Corp | ▼ | $113.02B |
| MMM 3m Co | ▶ | $84.97B |
| BSX Boston Scientific Corp | ▼ | $64.33B |
| BDX Becton Dickinson & Co | ▼ | $52.23B |
| MDLN Medline Inc. | ▶ | $47.28B |
| RMD Resmed Inc | ▼ | $34.47B |
| DXCM Dexcom Inc | ▼ | $32.47B |
| WST West Pharmaceutical Services Inc | ▼ | $27.03B |
| SOLV Solventum Corp | ▼ | $14.61B |
| BAX Baxter International Inc | ▶ | $13.07B |
| PEN Penumbra Inc | ▼ | $12.64B |
| GMED Globus Medical Inc | ▼ | $10.30B |
| PODD Insulet Corp | ▼ | $9.79B |
| GKOS Glaukos Corp | ▲ | $9.72B |
| TFX Teleflex Inc | ▼ | $5.53B |
| HAE Haemonetics Corp | ▼ | $5.38B |
| MMSI Merit Medical Systems Inc | ▼ | $5.33B |
| STVN Stevanato Group S.P.A. | ▲ | $5.16B |
| MMED Minimed Group, Inc. | ▶ | $4.92B |
| HTFL Heartflow, Inc. | ▲ | $4.20B |
| ICUI Icu Medical Inc/De | ▶ | $4.08B |
| IRTC Irhythm Holdings, Inc. | ▼ | $3.58B |
| PLSE Pulse Biosciences, Inc. | ▲ | $3.17B |
| ATRC Atricure, Inc. | ▲ | $2.85B |
| UFPT Ufp Technologies Inc | ▶ | $2.26B |
| INSP Inspire Medical Systems, Inc. | ▲ | $1.99B |
| LMAT Lemaitre Vascular Inc | ▶ | $1.85B |
| NVCR Novocure Ltd | ▲ | $1.64B |
| KMTS Kestra Medical Technologies, Ltd. | ▲ | $1.62B |
| ATEC Alphatec Holdings, Inc. | ▲ | $1.62B |
| TNDM Tandem Diabetes Care Inc | ▲ | $1.13B |
| IRMD Iradimed Corp | ▶ | $1.13B |
| DRTS Alpha Tau Medical Ltd. | ▲ | $1.08B |
| AORT Artivion, Inc. | ▼ | $1.06B |
| IART Integra Lifesciences Holdings Corp | ▲ | $1.03B |
| PRCT Procept Biorobotics Corp | ▲ | $1.01B |
| BVS Bioventus Inc. | ▶ | $908M |
| BBNX Beta Bionics, Inc. | ▲ | $863M |
| SGP Spyglass Pharma, Inc. | ▲ | $803M |
| MDXG Mimedx Group, Inc. | ▶ | $646M |
| KIDS Orthopediatrics Corp | ▶ | $573M |
| SSII Ss Innovations International, Inc. | ▶ | $517M |
| TCMD Tactile Systems Technology Inc | ▼ | $510M |
| DCTH Delcath Systems, Inc. | ▲ | $497M |
| ANGO Angiodynamics Inc | ▲ | $473M |
| SGHT Sight Sciences, Inc. | ▲ | $456M |
| BWAY Brainsway Ltd. | ▲ | $448M |
| CERS Cerus Corp | ▲ | $439M |
| NPCE Neuropace Inc | ▲ | $420M |
| RCEL Avita Medical, Inc. | ▲ | $403M |
| OFIX Orthofix Medical Inc. | ▼ | $382M |
| CARL Carlsmed, Inc. | ▲ | $366M |
| EMBC Embecta Corp. | ▶ | $355M |
| OBIO Orchestra Biomed Holdings, Inc. | ▲ | $328M |
| CLPT Clearpoint Neuro, Inc. | ▲ | $277M |
| MOBI Mobia Medical, Inc. | ▼ | $269M |
| ANIK Anika Therapeutics, Inc. | ▼ | $267M |
| TMCI Treace Medical Concepts, Inc. | ▲ | $252M |
| OSUR Orasure Technologies Inc | ▲ | $249M |
Hello. Good morning, everyone. Thanks for joining us today. I'm Eduardo Herdan. I'm part of the Morgan Stanley team. Today, I have the pleasure of being joined by Anshul Maheshwari, COO and CFO of ...
Truist Securities Adjusts SI-BONE Price Target to $25 From $23, Maintains Buy Rating MT Sep. 28 SI-BONE Receives FDA 510(k) Approval for Spinal Fusion System MT Sep. 28 SI-BONE, Inc. Receives U.S.
Spartan Medical® and SI-BONE® announce new partnership to expand access to advanced ultra–minimally invasive treatment options for sacroiliac joint dysfunction ...
On Oct. 16, 2026, SIBN is rated Neutral: its 90-day Total forecast sits in the middle 30% of the 5172 stocks scored that day.
For SIBN, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 41.0%, measured on 357 forecast dates between 2022-07-29 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is 40.0%, measured on 400 forecast dates between 2022-07-29 and 2026-09-16. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Si-Bone, Inc. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 16, 2026.
60 issuers in our coverage, SIBN included, share the SEC industry code Surgical & Medical Instruments & Apparatus. The largest are: Stryker Corp (SYK), 3m Co (MMM), Boston Scientific Corp (BSX), Becton Dickinson & Co (BDX), Medline Inc. (MDLN), Resmed Inc (RMD).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.
Signals, companies, plans: answered from live data.
I read Intratio's daily model signals, company data and your account to answer in seconds, in your language.